Three-Pronged attack tested against Tough-to-Treat blood cancer

This study tested a combination of three medicines—ibrutinib, fludarabine, and pembrolizumab—for adults with a hard-to-treat form of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see if using these drugs together could achieve a complete disappearance of cancer signs better than single drugs alone, especially for patients whose cancer had returned or had high-risk genetic features. The treatment involved taking ibrutinib pills daily, a short course of fludarabine, and pembrolizumab infusions for one year.